5 results
To examine the effect of L-dopa addition to optimal D2-blocking antipsychotic treatment on positive symptoms, negative symptoms, cognitive symptoms and extrapyramidal symptoms in schizophrenia.
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
The primary objective is to determine the effect of Transvamix on the pain quality item *unpleasantness*, relative to placebo. Secondary objectives include the assessment of general pain qualities, pain self-efficacy, general pain and pruritus…
The primary objectives of this add-on Phase 2 LTE study (see Table 1) are to evaluate the long-term safety and tolerability of IMP at three possible doses (ie, 15 mg/kg, 40 mg/kg, and 60 mg/kg) and to assess the effect of dose titration on the…
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care